Navigation Links
Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities
Date:5/16/2008

Appeals for Funds Focus on Millions of Children Still in Danger

NEW YORK, May 16 /PRNewswire/ -- The U.S. Fund for UNICEF and The Advertising Council today announced a partnership to distribute and promote a series of national public service announcements (PSAs) filmed by A-List celebrities, including Ben Stiller, Nicole Ritchie, Joel Madden, David Duchovny, Tea Leoni, and Paul Rudd, and designed to help survivors of the Myanmar cyclone. The Ad Council is distributing the new television, radio, print and online PSAs to 33,000 media outlets nationwide today.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/adcouncil/33309/

The biggest natural disaster since the tsunami, Cyclone Nargis has already claimed the lives of more than 100,000. But it is the millions of children in the country who need medicine, food, clean water, and shelter who are the most in danger. The celebrity PSAs, which were shot in Los Angeles by the award-winning GRAINEY Pictures (GPix), will appeal on the behalf of affected children by asking concerned Americans throughout the country for donations.

"In any disaster, it is children who suffer most. Vulnerable to hunger, disease and trauma, children require urgent life-saving assistance to survive and with millions of lives hanging in the balance, every second counts," said Caryl Stern, President and CEO, U.S. Fund for UNICEF. "We are so thankful to the Ad Council and the celebrities who are helping us get the word out, encouraging Americans around the country to do whatever it takes to help."

Of the affected populations across Yangon and Irrawaddy Divisions, approximately 30% to 40% are estimated to be children. UNICEF's priority is to assist the affected populations in Yangon and Irrawaddy Delta areas, especially the most vulnerable, children and women.

UNICEF is distributing life-saving su
'/>"/>

SOURCE The Ad Council
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Video: Ocean Spray Revitalizes Americans Naturally With Free Fuel for Their Bodies
2. Video: Pediatric Brain Tumor Foundation Gives $6 Million Grant to Duke
3. Video: 18th Annual Retirement Confidence Survey(R): Health Care, Economy Major Concerns in Workers Record Drop in Retirement Confidence
4. Video: Antifraud Compliance Getting More Complex for Hospitals
5. Video: Phoenix Suns Amare Stoudemire Kicks Off Program to Encourage Teens to Wake Up and Go to School
6. Video: National Association of School Nurses Launches Educational Program to Address Surge of Prescription Drug Abuse by Americas Youth
7. Video: Julianne Hough From Dancing With the Stars(TM) Has a New Partner: DR. SCHOLLS(R) FOR HER
8. Video: Start! Walking America: The American Heart Associations National Start! Walking Day Is April 16
9. Video: U.S. Olympic Hopefuls Featured in National Campaign to Combat Childhood Obesity
10. Video: Senators and CEOs Urge Passage of Health IT Bill Now
11. Video: Rubber Hits the Road as Trojan(R) Campaigns for Sexual Health in America to Evolve
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8